BS_13CGKADW
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 172.79894875164257
- age_years
- 5.077
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.341
- ANDROGEN_RESPONSE+0.276
- BILE_ACID_METABOLISM+0.257
- MYOGENESIS+0.253
- PANCREAS_BETA_CELLS+0.234
- UV_RESPONSE_DN+0.228
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.222
- KRAS_SIGNALING_DN+0.220
- ADIPOGENESIS+0.209
- OXIDATIVE_PHOSPHORYLATION+0.198
Top 10 suppressed
- MYC_TARGETS_V2-0.554
- E2F_TARGETS-0.514
- G2M_CHECKPOINT-0.479
- DNA_REPAIR-0.435
- WNT_BETA_CATENIN_SIGNALING-0.429
- MYC_TARGETS_V1-0.397
- ANGIOGENESIS-0.387
- UNFOLDED_PROTEIN_RESPONSE-0.272
- INTERFERON_ALPHA_RESPONSE-0.259
- MITOTIC_SPINDLE-0.259
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_3PYESPHA | Ganglioglioma | — | 0.887 |
| 2 | BS_VMMJYN8Z | Ganglioglioma | — | 0.877 |
| 3 | BS_TMTV769C | low-grade glioma | — | 0.854 |
| 4 | SRR614563 | GTEX | — | 0.843 |
| 5 | BS_ME3HKN2C | Ganglioglioma | — | 0.839 |
| 6 | BS_CGB2WS2A | pilocytic astrocytoma | — | 0.839 |
| 7 | BS_SFKZSJN1 | low-grade glioma | — | 0.836 |
| 8 | SRR8518242 | — | F | 0.833 |
| 9 | SRR1387264 | GTEX | — | 0.822 |
| 10 | BS_ET8CJXSF | pilocytic astrocytoma | — | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.341 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.276 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.257 | Inavolisib | — uncovered |
| MYOGENESIS | 0.253 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.234 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.228 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.222 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.209 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.198 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.181 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.178 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.156 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.119 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.115 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.112 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.095 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.032 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.031 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.025 | Inavolisib | — uncovered |